AURA
What one share of Aura Biosciences holds
Biological Products, (No Diagnostic Substances)
We are a clinical-stage biotechnology company developing precision therapies to treat solid tumors designed to preserve organ function. Our lead candidate bel-sar is in late-stage clinical development for the treatment of patients with early choroidal melanoma (defined as small choroidal melanoma and/or indeterminate lesions) and is also in clinical development for other ocular oncology indications and bladder cancer.
Aura Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.77 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.40 |
| Cash and investments | $0.66 |
| Book value | $3.05 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | — | −$1.96 | $0.04 | −$1.86 | — | $5.18 |
| 2023 | — | −$1.93 | $0.02 | −$1.63 | — | $4.58 |
| 2024 | — | −$1.75 | $0.03 | −$1.63 | — | $3.04 |
| 2025 | — | −$1.76 | $0.01 | −$1.41 | — | $2.15 |